After Career in Research, Lewis to Join NCCN as Chief Scientific Officer

Why It Matters

Lewis’s unique blend of clinical, academic, and industry experience equips NCCN to shape faster, evidence‑based oncology guidelines and improve patient access as regulatory pathways tighten.

Key Takeaways

• Lewis joins NCCN as chief scientific officer in May 2026
• Brings over a decade of phase‑1 trial leadership from Novartis
• Will help align NCCN guidelines with faster FDA approval pathways
• Emphasizes AI and patient‑access initiatives to streamline drug development

Pulse Analysis

The National Comprehensive Cancer Network, best known for its evidence‑based Clinical Practice Guidelines that influence 95% of cancer treatment decisions, has bolstered its leadership with the addition of Dr. Nancy L. Lewis as chief scientific officer. Lewis’s career spans bedside oncology, academic research, and senior roles at Novartis, giving her a panoramic view of the drug development pipeline. Her expertise in phase‑1 trials equips NCCN to evaluate emerging therapies more rigorously, ensuring that guideline updates reflect the latest scientific breakthroughs while maintaining the network’s reputation as the gold standard for clinicians and payers alike.

Regulatory momentum is reshaping oncology drug approval. The FDA’s recent initiatives aim to cut the traditional 10‑15‑year, $2 billion development cycle by streamlining trial requirements and embracing adaptive designs. In this environment, NCCN’s guidelines become even more critical for translating accelerated approvals into real‑world practice. Lewis’s appointment signals a strategic push to synchronize guideline revisions with faster FDA pathways, helping providers adopt novel treatments confidently and enabling payers to align reimbursement with the most current evidence.

Beyond regulatory alignment, Lewis is championing the integration of artificial intelligence into every stage of drug development. From target discovery to toxicity prediction and trial endpoint optimization, AI promises to reduce both time and cost. Coupled with her focus on patient‑access programs and collaboration with advocacy groups, Lewis aims to ensure that breakthroughs reach patients swiftly and equitably. Her vision positions NCCN at the forefront of a data‑driven, patient‑centric oncology ecosystem, where guidelines, technology, and policy converge to improve outcomes.